Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

• Status: Completed
• Trial end date: 2016-08-11
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study was to assess the effects of subcutaneous sumatriptan alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan concomitant therapy on resting blood pressure in healthy adults.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Amgen
• Treatments: Erenumab; Sumatriptan

Criteria

Inclusion Criteria:

• Healthy male and female subjects ≥ 18 to ≤ 55 years old

• Good general health

• Laboratory results within range

• Other Inclusion Criteria May Apply

Exclusion Criteria:

• Female subjects pregnant or breastfeeding

• An unstable medical condition

• History of cancer

• Active liver disease

• Positive Hepatitis B or Hepatitis C

• Unwilling or unable to limit alcohol consumption

• Unable to refrain from strenuous exercise

• Other Exclusion Criteria May Apply